Cyclophosphamide
Central Nervous System Neoplasm
Explore 48 assets in Central Nervous System Neoplasm →Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
UNICANCER
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03012620CT.gov Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types | — | Completed | — | — | — |
NCT02502708CT.gov Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | — | Completed | — | — | — |
NCT01356290CT.gov Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors | — | Recruiting | — | — | — |
NCT01639911CT.gov Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | — | Completed | — | — | — |
NCT01505569CT.gov Auto Transplant for High Risk or Relapsed Solid or CNS Tumors | — | Completed | — | — | — |
NCT00621036CT.gov Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma | — | Withdrawn | — | — | — |
NCT00623077CT.gov MT2004-30: Tomotherapy for Solid Tumors | — | Terminated | — | — | — |
NCT00238173CT.gov Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors | — | Terminated | — | — | — |
NCT00078988CT.gov High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas | — | Completed | — | — | — |
NCT00047281CT.gov Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma | — | Completed | — | — | — |
Show 16 more trialsShow fewer
NCT00392886CT.gov Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors | — | Unknown | — | — | — |
NCT00074165CT.gov Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen | — | Terminated | — | — | — |
NCT00730613CT.gov Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma | — | Completed | — | — | — |
NCT00025558CT.gov Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer | — | Completed | — | — | — |
NCT00003567CT.gov Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | — | Terminated | — | — | — |
NCT00007982CT.gov Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer | — | Completed | — | — | — |
NCT00331526CT.gov Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme | — | Completed | — | — | — |
NCT00003926CT.gov Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | — | Terminated | — | — | — |
NCT00014573CT.gov Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer | — | Completed | — | — | — |
NCT00003141CT.gov Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors | — | Completed | — | — | — |
NCT00008008CT.gov Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma | — | Completed | — | — | — |
NCT00003173CT.gov High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors | — | Completed | — | — | — |
NCT00003185CT.gov Biological Therapy in Treating Patients With Glioblastoma Multiforme | — | Completed | — | — | — |
NCT00004024CT.gov Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma | — | Completed | — | — | — |
NCT00313521CT.gov Thiotepa and Radiation Therapy in Treating Young Patients With Newly Diagnosed Malignant Brain Tumors | — | Unknown | — | — | — |
NCT00002619CT.gov Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Central Nervous System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | UNICANCER | P3 | BB · 69 |
| Procarbazine | Universitätsmedizin Mannheim | P3 | BBB |
| Vincristine Sulfate | Northwestern University | P3 | BBB |
| Irinotecan | EpicentRx, Inc. | P2 | BBB |
| Etoposide | NewLink Genetics Corporation | P3 | BBB |
| Gefitinib | Memorial Sloan Kettering Cancer Center | P2 | BBB |
| Carboplatin | OHSU Knight Cancer Institute | P3 | BBB |
| Isocyclophosphamide | Masonic Cancer Center, University of Minnesota | P3 | BBB |
| Camustine | Lisata Therapeutics, Inc. | P3 | BBB |
+42 more in the Central Nervous System Neoplasm cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Central Nervous System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-central-nervous-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →